
About this episode
On the heels of the success of GLP-1s like Ozempic, other peptide treatments are flooding the marketplace—and advertising spaces. But even as the Trump administration’s FDA discusses approving more treatments and the businesses selling them proliferate, many peptides are sitting in a legal and medical gray area. So how real - and safe - is this peptide hype?
Guest: Kate Knibbs, senior writer at WIRED.
Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.
Podcast production by Rob Gunther, Evan Campbell, Madeline Thames-Ducharme and Patrick Fort.
Paige Osburn is the senior supervising producer of What Next and What Next TBD.
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time What Next | Daily News and Analysis publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from What Next | Daily News and Analysis

Did ICE Drive Him to His Death?
What Next | Daily News and Analysis

Dems Can Beat MAGA. Here’s How.
What Next | Daily News and Analysis

Question Everything: The Sunscreen Paradox
What Next | Daily News and Analysis

Meta Settled. Is it a "Reckoning?"
What Next | Daily News and Analysis